Sheoran et al., IJPSR, 2020; Vol. 11(3): 1373-1379. E-ISSN: 0975-8232; P-ISSN: 2320-5148 International Journal of Pharmaceutical Sciences and Research 1373 IJPSR (2020), Volume 11, Issue 3 (Research Article) Received on 24 May 2019; received in revised form, 30 July 2019; accepted, 03 February 2020; published 01 March 2020 PREPARATION, OPTIMIZATION AND CHARACTERIZATION OF LETROZOLE NANO- LIPOSOMES Reena Sheoran 1 , Sukhbir Lal Khokra 1 and Harish Dureja * 2 Institute of Pharmaceutical Sciences 1 , Kurukshetra University, Kurukshetra - 136119, Haryana, India. Department of Pharmaceutical Sciences 2 , Maharshi Dayanand University, Rohtak - 124001, Haryana, India. ABSTRACT: Objective: Nanoliposomes of letrozole a drug used for breast cancer treatment were formulated. The present investigation was aimed to optimize the phospholipids concentration by formulating a series of nanoliposomes formulation and their characterization. Methods: Nanoliposomes were prepared using reverse-phase evaporation technique employing diverse ratios of soya lecithin and cholesterol concentration. The effect of various factors was studied on size, polydispersity index, loading capacity and entrapment efficiency of nanoliposomes. The prepared nanoliposomes were analyzed using DSC and ATR spectroscopy for drug-excipients compatibility. Results: The smallest particle size and polydispersity index (99.45, 0.262) highest entrapment (87.24 ± 0.59) and loading capacity (56.89 ± 0.39) was observed in batch NL8. The disappearance of drug peak in DSC indicates the dissolution of the drug in a polymer matrix. The ATR spectroscopy results show there was no interaction between components and drug is stable in the formulated nanoliposomes. Conclusion: It is concluded that the concentration of soya lecithin and cholesterol were critical parameters that affect the encapsulation of letrozole in the formulation and optimization of nanoliposomes. INTRODUCTION: Breast cancer is one of the frequently diagnosed cancer and the leading causes of death in women worldwide 1-2 . Breast cancer recurrence risk continues for an indefinite period after surgery, radiation and medical therapy 3 . Based on the diverse expression of estrogen receptor-α (ER-α), progesterone receptor, claudin, cytokeratin, human epidermal growth factor receptor-2 (HER2), and other molecular markers, a number of subtypes of breast cancer have been identified, such as luminal A, luminal B, HER2, basal-like and claudin-low 4 . QUICK RESPONSE CODE DOI: 10.13040/IJPSR.0975-8232.11(3).1373-79 This article can be accessed online on www.ijpsr.com DOI link: http://dx.doi.org/10.13040/IJPSR.0975-8232.11(3).1373-79 The growth of breast cancer depends directly on the action of estrogen; hence reductions in recurrence have been achieved by antagonizing the action of estrogen 5-7 . One strategy is to antagonize estrogen receptor (ER), predominantly with tamoxifen (selective estrogen-receptor modulator), which has become the gold standard for the treatment of ER+ breast cancer patients over the past decades 8-10 . On the other hand, inhibition of estrogen production, which is also known as estrogen deprivation therapy, is emerging as another important treatment strategy for estrogen- dependent breast cancer 11-12 . Before the advent of anti-human epidermal growth factor receptor 2 (HER2) therapies, the survival of metastatic HER2- positive breast cancer patients was quite poor 13 . The advent of targeted therapies has led to impressive improvements in survival 14 . Tamoxifen has been a standard first-line endocrine therapy for Keywords: Nanoliposome, Letrozole, Breast cancer, Optimization, Characterization Correspondence to Author: Dr. Harish Dureja Professor, Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak - 124001, Haryana, India. E-mail: harishdureja@gmail.com